Search

Displaying results 3481 - 3490 of 7284 in total
  1. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    FDA-approved therapy for this condition. … In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.

  2. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative

  3. Target

    Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial

    go.drugbank.com/bio_entities/BE0002254
    TargetHumans

    Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed

    Synonyms: Iron-sulfur subunit of complex II
  4. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970. … Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.

    Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor Antagonists
  5. Drug

    Fuzapladib

    go.drugbank.com/drugs/DB19478
    Experimental

    Fuzapladib has a monoisotopic molecular weight of 379.12 Da. … Fuzapladib is a small molecule drug. The usage of the INN stem '-pladib' in the name indicates that Fuzapladib is a phospholipase A2​ inhibitor.

    Categories: Phospholipases A, antagonists & inhibitors
  6. Drug

    Umibecestat

    go.drugbank.com/drugs/DB19898
    Experimental

    Umibecestat has a monoisotopic molecular weight of 513.08 Da. … Umibecestat is a small molecule drug. The usage of the INN stem '-becestat' in the name indicates that Umibecestat is a beta secretase inhibitor.

  7. Drug

    Tomicorat

    go.drugbank.com/drugs/DB20822
    Experimental

    Tomicorat has a monoisotopic molecular weight of 527.21 Da. … Tomicorat is a small molecule drug. The usage of the INN stem '-corat' in the name indicates that Tomicorat is a glucocorticoid receptor agonist.

  8. Drug

    Zaloglanstat

    go.drugbank.com/drugs/DB21495
    Experimental

    Zaloglanstat has a monoisotopic molecular weight of 452.12 Da. … Zaloglanstat is a small molecule drug. The usage of the INN stem '-glanstat' in the name indicates that Zaloglanstat is a prostaglandin synthase inhibitor.

  9. Drug

    Zevaquenabant

    go.drugbank.com/drugs/DB21590
    Experimental

    Zevaquenabant has a monoisotopic molecular weight of 547.11 Da. … Zevaquenabant is a small molecule drug. The usage of the INN stem '-nabant' in the name indicates that Zevaquenabant is a cannabinoid receptor antagonist.

  10. Drug

    Setidegrasib

    go.drugbank.com/drugs/DB21670
    Investigational

    Setidegrasib has a monoisotopic molecular weight of 1116.48 Da. … Setidegrasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Setidegrasib is a Ras protein inhibitor.